What Happens When Anti-VEGF Injections Stop Working
Understanding Anti-VEGF Treatment Resistance
According to published data (PMC, 2023), between 15 and 40 percent of eyes with wet AMD fail to respond or only partially respond to anti-VEGF therapy. Treatment resistance is a recognized challenge that retina specialists encounter regularly. If your injections seem less effective than they once were, you are not alone, and your doctor has strategies to address the problem.
Resistance does not mean your situation is hopeless. Multiple alternative approaches exist, and your retina specialist can adjust your treatment to regain disease control in most cases.
According to published data (PMC, 2021), two distinct patterns of treatment failure are recognized in wet AMD. Primary non-response means your eye showed no meaningful improvement from the start of treatment. Tachyphylaxis means you responded well at first but lost the effect over time as your eye became less sensitive to the drug. In one study of 63 treatment-naive wet AMD eyes, 22.2 percent showed primary non-response and 12.7 percent developed tachyphylaxis within one year.
Your retina specialist identifies which pattern applies to you based on your OCT imaging history, visual acuity trends, and how quickly fluid returns after each injection. This distinction guides the next treatment step.
Your retina specialist monitors your OCT imaging at every visit. If fluid persists despite regular injections, if the retina does not dry out between doses, or if fluid returns faster than before, your doctor recognizes that your current regimen is losing effectiveness. According to the NEI (2023), ongoing OCT monitoring at each visit is essential for detecting loss of response before significant vision loss occurs, which is a key reason regular follow-up matters even when your vision seems stable.
Treatment Options When Your Current Drug Stops Working
The most common first step for treatment resistance is switching to a different anti-VEGF medication. According to AAO EyeNet, among patients with attenuated response treated with ranibizumab or bevacizumab, switching to the other agent restored fluid reduction in 81 percent of cases, and 50 percent improved with the very first switch injection. Your retina specialist may switch you to an agent with a different mechanism, such as moving from a VEGF-A-only inhibitor to faricimab, which blocks both VEGF-A and angiopoietin-2.
Sometimes the issue is not the medication but the interval between doses. Your retina specialist may shorten the time between injections to maintain higher drug levels in your eye. A patient on an eight-week interval who starts showing fluid recurrence may do better at six or four weeks. Your doctor uses OCT findings to find the interval that keeps your retina dry.
According to AAO EyeNet, for polypoidal choroidal vasculopathy (PCV, a wet AMD subtype more common in Asian populations), PDT alone or combined with anti-VEGF outperforms anti-VEGF monotherapy. If your retina specialist identifies PCV as the cause of your treatment resistance, adding PDT may achieve the vessel closure that anti-VEGF alone cannot. Combination therapy using reduced-fluence PDT with anti-VEGF is the standard approach for these cases.
According to published reviews (Review of Ophthalmology, 2024), combination triple therapy uses anti-VEGF injection, photodynamic therapy, and a corticosteroid to target three aspects of disease at once: VEGF-driven vessel growth, existing abnormal vessel structure, and retinal inflammation. Retina specialists reserve triple therapy for cases that have not responded to simpler strategies. It is not a first-line option but can help when other approaches have been exhausted.
Emerging and Investigational Options
According to AAO EyeWiki (2023), faricimab, which blocks both VEGF-A and angiopoietin-2, is being explored as a switch option for patients resistant to VEGF-A-only agents. Its distinct dual mechanism may provide disease control where single-target drugs cannot. High-dose aflibercept (8 mg) delivers more medication per injection and may overcome partial responses seen with the standard 2 mg dose.
According to Retina Today (2025), investigational sustained-release implants containing tyrosine kinase inhibitors have shown promise in early clinical trials for patients with wet AMD. These implants release medication over months, potentially reducing or eliminating the need for repeated injections. Phase 3 trials are ongoing, and your retina specialist can discuss whether clinical trial participation is an option for you.
While emerging treatments are promising, multiple proven strategies exist right now for managing anti-VEGF resistance. According to the AAO and NEI (2023), patients who stop improving on their current injection should inform their doctor right away because early recognition and fast action lead to better long-term visual outcomes. Your retina specialist can work through the available options to find what works for your eyes.
Questions About Anti-VEGF Treatment Resistance
No. Switching anti-VEGF agents restores fluid control in the majority of patients. Each medication has a slightly different mechanism, and an eye that no longer responds to one drug often responds to another. Your retina specialist has multiple medications and strategies available to regain disease control.
Your retina specialist monitors your OCT imaging at every visit. Persistent or recurring fluid on imaging, declining visual acuity, or the need for increasingly shorter intervals between injections all suggest fading treatment response. You may also notice increased blurriness or distortion between appointments. Report any vision changes to your doctor between scheduled visits.
Do not stop treatment on your own. Even a partially effective medication is slowing disease progression. Stopping all anti-VEGF treatment allows unchecked vessel growth and fluid accumulation, which can cause rapid, permanent vision loss. Talk to your retina specialist about switching or adjusting your treatment rather than stopping.
Yes. Share your concerns with your retina specialist. If you feel your current treatment is not working as well as it used to, your doctor will review your imaging trends and consider a switch. Patients and doctors make this decision together based on clinical evidence and your treatment history.
Your retina specialist evaluates your response after each injection. If fluid persists after several consecutive treatments at an appropriate interval, your doctor may recommend a switch. There is no fixed waiting period; the decision depends on how your retina responds to the current regimen and whether the trend is worsening.
Clinical trials for new wet AMD treatments, including sustained-release implants and novel drug mechanisms, are ongoing at many retina centers. Your retina specialist can tell you whether any trials recruiting at their center or nearby institutions match your situation. Trial participation gives you access to investigational treatments while contributing to advances in AMD care.
Stay Engaged With Your Treatment Team
If your anti-VEGF injections seem less effective, contact your retina specialist to discuss your options. Early recognition of treatment resistance and timely adjustment give you the best chance of preserving the vision you rely on.